Asabys Partners, a venture capital firm and member of CataloniaBio & HealthTech, has participated in Medasense Biometrics Ltd’s €15.2-million Series C round of funding along with investors such as Baxter and Olive Tree Ventures, among others.
Medasense was founded in Tel Aviv in 2008 by Galit Zuckerman and has offices in Barcelona and Berlin.
The company has developed sensor technology based on artificial intelligence (PMD-200) to monitor the pain of sedated patients and optimise the administration of anaesthesia, in critical-care and operating-room settings where patients are unable to communicate. Currently, the company is active in implementing its technology for Covid-19 ventilated patients.
The PMD-200 is distributed in Europe exclusively by Medtronic. The goal for the coming years is to expand and consolidate its presence in Europe and enter in US.
Photo: Josep Lluís Sanfeliu and Clara Campàs, partners of Asabys, in the headquarters located at the passeig de Gracia in Barcelona - © Asabys Partners
El equipo de investigadores observó cambios en el...
El gen AtCDF3 promueve una mayor producción de az...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Una investigación liderada por científicos del IIBB-CSIC y del CIBER...
